Percutaneous Tumor Ablation Vs Partial Nephrectomy for Small Renal Mass: the Impact of Histologic Variant and Tumor Size
NCT ID: NCT06829888
Last Updated: 2025-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
955 participants
OBSERVATIONAL
2007-01-01
2019-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Feasibility Study for a Multicentre Randomised Controlled Trial to Compare Surgery With Needle Ablation Techniques in People With Small Renal Masses (4cm)
NCT01608165
Patient Reported Outcome After Nephron Sparing Treatment of Small Renal Tumours
NCT04040530
Tumor Rupture During Robotic Partial Nephrectomy
NCT07065825
Oncological and Functional Outcomes of Laparoscopic Partial Nephrectomy in Renal Cell Carcinoma Stages T1 Versus T2a: Prospective Comparative Study.
NCT05486871
Imaging-Guided Classification for Endophytic Renal Tumors: PN Strategies & Outcomes
NCT06954571
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
localized (cN0 M0) renal mass (cT1) treated with partial nephrectomy
patients with clinically localized (cN0 M0) renal mass (cT1) treated with partial nephrectomy
No interventions assigned to this group
localized (cN0 M0) renal mass (cT1) treated with percutaneus RFA
patients with clinically localized (cN0 M0) renal mass (cT1) treated with percutaneus RFA
No interventions assigned to this group
localized (cN0 M0) renal mass (cT1) treated with percutaneous cryo
patients with clinically localized (cN0 M0) renal mass (cT1) treated with percutaneous cryo
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Renal neoplasm of clinical stage T1a (≤4 cm) N0M0
* Age \>18 years
* Informed consent
* Absence of other neoplasm
Exclusion Criteria
* Patients who are candidates for radical nephrectomy
18 Years
82 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lorenzo Bianchi, MD
Role: PRINCIPAL_INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRYO-BO-2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.